Funds and prices
Overview
Actively managed equity portfolio investing worldwide in biotech companies.
Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Easy access to the global biotech sector.
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
蜜豆视频's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
Investors benefit from a global investment platform of 蜜豆视频 Asset Management.
Risks
Features
| Product category |
蜜豆视频 Equity Funds
蜜豆视频 Sector Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
蜜豆视频 Asset Management (Americas) LLC, New York
|
| Fund management |
蜜豆视频 Fund Management (Luxembourg) S.A., Luxembourg
|
| Custodian bank |
蜜豆视频 Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
蜜豆视频 AG, Stockholm
|
| Day of inception |
October 15, 1996
|
| Currency of account |
USD
|
| Close of financial year |
November 30
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Management fee |
1.63% p.a.
|
| Total expense ratio (TER) |
2.10% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI US Investable Market Biotechnology 10/40 Index (r)
|
| ISIN |
LU0069152568
|
| Bloomberg Ticker |
蜜豆视频EBIO LX
|
| Telekurs Id |
EQBIO
|
Performance and Prices
Percentage growth
as of April 3, 2024| USD(%) | EUR(%) | |
| YTD | ||
| 1M | ||
| 3M | ||
| 6M | ||
| 1Y | -0.11 | 0.50 |
| 2Y | ||
| 3Y | -11.03 | -3.31 |
| 5Y | 10.94 | 15.11 |
| ø p.a.5Y | 2.10 | 2.85 |
Current data
| Net asset value | 03.04.2024 | USD 683.01 |
| High - last 12 months | 08.01.2024 | USD 748.63 |
| Low - last 12 months | 27.10.2023 | USD 579.19 |
| Assets of the unit class in mn | 03.04.2024 | USD 405.00 |
| Total product assets in mn | 03.04.2024 | USD 475.26 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 29.02.2024 | 17.06% | 19.01% |
| Sharpe Ratio | 29.02.2024 | -0.09 | 0.02 |
| Risk Free Rate | 31.03.2024 | 4.15% | 2.15% |
Structures
By the 10 largest equity positions (in %, as of February 29, 2024)
|
|
|
| Vertex Pharmaceuticals Inc | 9.57 |
| Moderna Inc | 9.31 |
| Alnylam Pharmaceuticals Inc | 7.04 |
| Regeneron Pharmaceuticals Inc | 5.46 |
| AbbVie Inc | 4.88 |
| Neurocrine Biosciences Inc | 4.46 |
| Amgen Inc | 4.09 |
| Genmab A/S | 4.07 |
| Arrowhead Pharmaceuticals Inc | 3.79 |
| Gilead Sciences Inc | 3.78 |
Fees
Distributions
Authorisations
Literature
|
Document type
|
Document Language
|
|
| Prospectus |
|
|
| Country supplement |
|
|
| Key Information Document |
|
|
| Past performance |
|
|
| Previous performance scenario |
|
|
| Statutes / Management regulations |
|
|
| ESG Disclosure |
|
|
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|
